Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
1. Merck stock shows short-term strength above key SMAs at $98.90. 2. Long-term resistance exists with a 50-day SMA of $99.64. 3. Analysts target Merck's stock at $124, suggesting 20.25% upside. 4. Pfizer's stock trend looks bearish, struggling at $26.30. 5. Merck is favored over Pfizer in the upcoming earnings showdown.